REGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Regeneron Pharmaceuticals Inc (REGN) does not present a strong buy opportunity at this time for a beginner investor with a long-term focus. The technical indicators suggest a neutral to slightly bearish trend, and while there are positive catalysts such as the European Commission's approval of Dupixent and a promising collaboration with Telix, the financial performance shows declining net income and EPS. Additionally, the options data indicates bearish sentiment with a high put-call ratio. Given the investor's profile and the lack of immediate strong buy signals, holding the stock or waiting for a better entry point is recommended.
The MACD is negatively expanding (-0.632), indicating bearish momentum. RSI is neutral at 38.827, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 742.34), suggesting potential downside risk.
European Commission approval of Dupixent for treating chronic spontaneous urticaria in children.
Collaboration with Telix to develop next-generation radiopharmaceuticals, with a $40 million upfront payment and potential earnings of up to $2.1 billion.
Declining net income (-7.97% YoY) and EPS (-2.97% YoY) in Q4
Seasonal headwinds and potential biosimilar competition for Eylea.
Bearish sentiment in options data with high put-call ratios.
In Q4 2025, revenue increased by 2.51% YoY to $3.88 billion, but net income dropped by 7.97% YoY to $844.6 million. EPS declined by 2.97% YoY to 7.84, while gross margin improved slightly to 89.4%.
Analyst ratings are mixed, with several firms raising price targets but expressing concerns about Eylea headwinds and biosimilar competition. Price targets range from $765 to $975, with an average around $835. Positive views focus on Dupixent's dominance and undervalued pipeline opportunities.
